EURASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES
Innovative Academy Research Support Center
UIF = 8.3 | SJIF = 7.921 www.in-academy.uz



PAIN PERCEPTION AND MANAGEMENT: ASSESSING OUR CURRENT POSITION

Nurulloyev Jo'rabek Shavkiddinovich
Assistant reacher of the Alfraganus university
ORCID ID: 0009-0003-4777-1881
Email: JurabekDoctor@mail.ru
Mirzayeva Adiba Khamdamovna
Assistant reacher of the Alfraganus university
ORCID ID:0000-0002-8670-7431
Email: adiba.mirzayeva@mail.ru
Nishanbayeva Firuza Murodovna
Assistant reacher of the Alfraganus university
ORCID ID: 0009-0007-0093-4806
Email: Drmalikovafiruza8286@mail.ru
https://doi.org/10.5281/zenodo.10842065

ARTICLE INFO

Received: 12th March 2024
Accepted: 18th March 2024
Online: 20th March 2024

KEYWORDS

Inflammatory bowel disease, polymyalgia, Nociceptive Pain, Neuropathic Pain, Dopamine.

ABSTRACT

As per the definitions provided by the International Association for the Study of Pain (IASP), nociception is described as "the neural mechanisms responsible for encoding and processing harmful stimuli," while pain is characterized as "an unwanted sensory and emotional experience linked with actual tissue damage". Pain serves as a signal eliciting both reflexive and conscious responses aimed at safeguarding the body from potential harm. A wide array of stimuli, including heat, inflammation, necrosis, and muscle spasm, among others, can trigger pain sensations. Numerous chemical mediators indicative of painful conditions have been identified. Pain and inflammation can manifest in the course of various diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease, and polymyalgia. In the majority of cases, pain is a constant companion in diabetic nephropathy. In the United States of America (USA), over fifty million individuals face partial or complete disability due to pain, significantly impacting their quality of life. Recent research conducted by the US Center for Healthcare Statistics estimates that approximately 32.8% of people in the USA suffer from chronic pain. Various synthetic and natural agents exhibiting potent pain-relieving properties are readily accessible for managing such pain. The objective of this review is to explore different facets of pain perception, evaluate the current status of available therapies for managing various pain conditions, and discuss future directions considering the

present limitations and side effects associated with clinically used medications.

PREVALENCE OF PAIN

Crook et al. conducted a prevalence study in which they randomly selected patients who regularly visited their general practitioners in the vicinity of Toronto, Canada, and analyzed the prevalence data. The survey was administered via telephone calls and achieved a response rate of 95%. The findings of the survey were intriguing, indicating that pain tends to increase with age, emerging as a significant issue in older age groups. According to a study by Kending et al., the prevalence of temporary pain equals that of permanent pain. This latter study involved a random sample drawn from the community.

It is worth noting that older individuals often report pain in different locations. However, most studies indicate pain localized to specific areas of the body. While prevalence rates may vary across surveys, there have been emerging trends based on the temporary definition of pain. For instance, joint pain appears to be reported at twice the prevalence rate among individuals aged 65 and above compared to younger cohorts. Moreover, there seems to be a decline in pain as individuals surpass the age of 75. Grimby et al. observed a nearly 20% decrease in joint pain among male patients aged 75 to 79, and an 8% decrease in those over 90. Although data from female patients are less consistent, the general trend appears similar, with joint pain decreasing from 35% to 29%. This study also found that foot and leg pain tend to increase with age. Conversely, a higher incidence of headaches has been reported between the ages of 45 and 50.

Several studies have indicated that as age increases, so does the incidence of headaches. Certain types of pain, such as visceral pain, dental pain, and abdominal pain, have been observed to decrease with age. Thoracic pain becomes more prevalent in late middle age, similar to cardiovascular diseases. However, data on back pain exhibit inconsistencies across different age groups. While Harkins et al. and Von Korff et al. reported a slight increase in back pain with age, several other studies have shown contrasting results. An overview of the topic suggests that the prevalence rates of abdominal, head, and thoracic pain decrease among older individuals, whereas musculoskeletal joint pain gradually rises at least until the age of 80. Although back pain prevalence varies in different studies, it appears to peak in late middle age or early old age and subsequently decline with advancing age.

Most epidemiological studies have demonstrated that females exhibit a higher prevalence of pain compared to males of the same age, although some studies have shown conflicting results. However, middle-aged females report a 15% higher incidence of headaches. This potential gender difference diminishes in individuals over the age of 70. Abdominal and visceral pain cases are most commonly observed in females aged 18 to 40 years, with similar results

seen between the sexes in older individuals. In contrast, gender differences are not prevalent in joint pain and back pain, both of which tend to increase with age.

TYPES OF PAIN

Pain can be categorized into two main types: acute pain and chronic pain (refer to Fig. 1). Acute pain typically arises from direct tissue damage and is often described as sharp and sudden. It frequently accompanies conditions such as myocardial infarction (MI), trauma, burns, and surgical procedures. Acute pain can be further divided into two phases. During the initial phase, the brain signals the body to react to the injurious stimulus, lasting for several seconds. Subsequently, the body initiates protective mechanisms to repair the damaged tissue, a phase also known as the sub-acute phase, which may persist for hours or days.

Chronic pain, on the other hand, persists for an extended period, posing challenges for effective treatment. Even after tissue healing, chronic pain often lingers without a discernible cause. Chronic pain itself appears to be a pathological condition warranting therapeutic intervention. It can be subcategorized into neuropathic pain, nociceptive pain, and inflammatory pain.



Fig. (1).Three types of Pain. Nociceptive always originates in specific situations like in case of trauma. Neuropathic pain results in case of nerve damage and inflammatory pain. In **inflammatory pain, inflammatory mediators are involved in sensitization of nociceptors.**

1. Nociceptive Pain

Nociceptive pain typically initiates with the activation of primary afferent neurons distributed throughout the body, even in the absence of sensitization. It is characterized by a normal and acute sensation of pain. This mechanism serves as an early warning system in response to potential tissue damage. Due to the risk of impending harm, surgical and medical interventions are often necessary for the management of nociceptive pain. It is crucial to note that nociceptive pain should not be permanently suppressed, as it serves as a vital physiological alert system. Nociceptive pain can be further classified into two categories: somatic nociceptive pain and visceral nociceptive pain. Somatic nociceptive pain originates from bones and muscles,

presenting as a dull and throbbing sensation. Visceral nociceptive pain commonly arises from solid and hollow visceral organs, characterized by painful cramping and squeezing sensations.

2. Inflammatory Pain

Inflammatory pain arises when inflammation triggers sensitization of peripheral nerve terminals, resulting in pain sensations, such as those seen in arthritis. Multiple physiological factors contribute to the onset of both inflammatory and non-inflammatory pain. Specifically, inflammatory pain can be effectively mitigated by non-steroidal anti-inflammatory drugs (NSAIDs) and steroids, as they are capable of reducing inflammatory responses without directly affecting antinociceptive actions.

3. Neuropathic Pain

Neuropathic pain emerges when damage affects a peripheral nerve or a group of nerves, leading to distinctive neuropathic pain sensations. This type of pain is frequently inked with conditions such as cancer chemotherapy and diabetes mellitus (DM) .

INFLAMMATION AND PAIN

Inflammatory mechanisms can be triggered by tissue damage, infection, or irritation. Typical symptoms such as redness (rubor), heat (calor), swelling (tumor), and pain (dolor) are associated with inflammation. Post-operative pain often exhibits these hallmark symptoms of inflammatory pain. In conditions like arthritis, inflammation persists, serving as the foundation for ongoing inflammatory pain. Various substances, including 5-HT, kinins, histamine, nerve growth factors (NGF), adenosine triphosphate (ATP), prostaglandins (PG), glutamate, leukotrienes, nitric oxide (NO), norepinephrine (NE), and protons, play roles in mediating both inflammatory pain and inflammation. These substances are released following tissue damage, initiating a cascade of inflammatory processes. Inflammatory mediators directly activate and sensitize primary afferent nerves. Some mediators also induce the release of additional inflammatory mediators from immune cells, forming a cascade of pro-inflammatory signals. These newly released mediators, along with chemicals in the inflammatory environment, attract immune cells, which accumulate in the damaged tissue. These immune cells act as sources of growth factors and cytokines, which significantly contribute to the development and modulation of hyperalgesia.

PAIN TRANSMISSION

At the synaptic cleft, a presynaptic action potential triggers the opening of calcium channels, leading to the release of various neurotransmitters into the synaptic cleft, including acetylcholine, dopamine, and gamma-aminobutyric acid (GABA). Opioid receptors also play a crucial role in pain transmission, with glutamate serving as a neurotransmitter in opioid receptors. Acetylcholine acts as a neurotransmitter in two distinct modalities: it can either facilitate the transmission of pain signals or inhibit it. When administered exogenously, acetylcholine reduces pain; however, in cases of injury such as tendinitis, locally released acetylcholine at the injury site may induce inflammation.

Dopamine contributes to pain transmission in a unique manner. Dopamine receptors are expressed in primary nociceptors as well as in spinal neurons located across different laminae in the dorsal horn of the spinal cord. This suggests that dopamine can modulate pain signals by acting at both presynaptic and postsynaptic target. This is consistent with observations in

Parkinson's disease, during which nerve degeneration leads to low concentrations of dopamine, resulting in the propagation of pain signals.

MODULATION OF PAIN

Pain modulation involves a diverse array of mechanisms that can either heighten or alleviate pain sensations. Pain modulation occurs at various levels within the body, including peripheral sites, the cortical areas of the brain, and the dorsal region of the spinal cord. D2 receptor agonists are ineffective in thermal nociception but are applicable in mechano-nociception treatment [60]. Catecholamines (norepinephrine and adrenaline) and serotonin influence pain perception at both spinal and supra-spinal levels. Inhibition of their reuptake at the synaptic cleft leads to pain attenuation. While serotonin and dopamine exhibit both nociceptive and anti-nociceptive activities, noradrenaline exclusively displays anti-nociceptive effects, which explains why drugs targeting serotonin-norepinephrine reuptake inhibition (SNRI) demonstrate potent anti-nociceptive properties. GABA receptors and glutamate transporters play pivotal roles in pain transmission within the synaptic cleft.

RECEPTORS INVOLVED IN PAIN PERCEPTION

Upon injury, sensory neurons within the central nervous system (CNS) receive an external stimulus and generate an internal electrical impulse known as an action potential. Afferent nerves stemming from these sensory neurons transmit sensory information from the peripheral nervous system (PNS) towards the CNS. Nociceptors, akin to sensory receptors, convey pain signals to the brain via the spinal cord in response to external stimuli. This process of pain transmission is commonly referred to as nociception. Below are several receptors implicated in pain transmission:

1. Opioid Receptors

Opioid receptors play a crucial role in pain modulation and anti-nociception. These receptors are widely distributed throughout the central nervous system (CNS) and the gastrointestinal tract (GIT). Functioning as inhibitory G-protein coupled receptors, opioid drugs exert their effects by targeting these receptors. Opioid receptors are classified into three main types:

(1) Delta receptors are found in both the brain and peripheral sensory neurons, and they contribute to pain perception as well as depressive disorders. (2) Kappa receptors are located in peripheral sensory neurons, the Substantia gelatinosa of the spinal cord, and the hypothalamus. They play a crucial role in the management of pain, stress, and depression-like conditions. (3) Mu receptors are situated in the intestine, peripheral sensory neurons, the Substantia gelatinosa of the spinal cord, and various regions of the brain including the cortex and thalamus. While all Mu receptors play a key role in analgesia, Mu1 receptors are particularly involved in pain perception. Additionally, Mu receptors are associated with other effects such as euphoria, respiratory depression, and reduced gastrointestinal motility.

Opioid drugs alleviate pain by binding to opioid receptors, leading to a hyperpolarization effect mediated by the opening of potassium channels and the closure of calcium and sodium channels. These drugs also inhibit the adenylyl cyclase enzyme. Important opioid drugs include fentanyl, morphine, and methadone, while naltrexone and naloxone are opioid receptor blockers.

2. Dopaminergic Receptors

Dopaminergic receptors are primarily situated in the central nervous system (CNS) and function as G-protein coupled receptors. There are five known types of dopaminergic receptors. Within these, D1 and D5 receptors (D1-like family) exhibit excitatory properties. They stimulate adenylyl cyclase, leading to the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). Conversely, D2, D3, and D4 receptors (D2-like family) are inhibitory in nature. They inhibit the adenylyl cyclase enzyme, resulting in decreased cAMP production. Additionally, D2, D3, and D4 receptors possess the ability to modulate calcium channel activity and potassium channel closure. Agents such as terguride, apomorphine, and bromocriptine serve as activators of D1 receptors, while ecopipam functions as a blocker of D1 and D5 receptors. On the other hand, medications like haloperidol, risperidone, and domperidone block D2, D3, and D4 receptors. Apomorphine, pramipexole, bromocriptine, and cabergoline act as agonists of D2 receptors. Among the dopaminergic activating receptors, D2, D3, and D4 receptors are notable for their analgesic effects.

3. Adrenergic Receptors

Adrenergic receptors, also known as adrenoceptors, are G-protein coupled receptors commonly activated by adrenaline and noradrenaline. These receptors are further categorized into two main types: alpha receptors and beta receptors.

(1) Alpha-adrenergic receptors comprise two significant subtypes: alpha-1 and alpha-2. Peripherally, alpha-1 receptors are located postsynaptically and exert excitatory effects, whereas alpha-2 receptors function as autoreceptors and play a role in the regulation of norepinephrine release.

Beta receptors encompass three important subtypes: beta-1, beta-2, and beta-3. Alpha-1 and beta-1 receptors mediate stimulatory responses, while alpha-2, beta-2, and beta-3 receptors predominantly elicit inhibitory responses. All alpha receptors contribute to blood vessel constriction and reduction in gastric emptying. Activation of alpha-1 receptors triggers the release of arachidonic acid, while alpha-2 receptors stimulate cyclic adenosine monophosphate (cAMP) synthesis. Subsequently, cAMP serves as a second messenger, facilitating the opening of calcium channels.

Agents such as tamsulosin, terazosin, and prazosin act as agonists of alpha-1 receptors, stimulating their activity. Conversely, medications like methyldopa, clonidine, and guanabenz activate alpha-2 receptors, earning them the designation of alpha-2 agonists. Mirtazapine and yohimbine are alpha-receptor blockers. The mechanisms through which alpha receptors operate align with their antinociceptive properties.

4. Lipoxygenase Enzymes

Lipoxygenase (LOX) enzymes are found in basophils, neutrophils, eosinophils, and mast cells, all originating from the myeloid lineage. These enzymes contain iron and are involved in the deoxygenation of polyunsaturated fatty acids within lipids. Phospholipase enzymes stimulate the production of arachidonic acid in the phospholipid bilayer. Subsequently, arachidonic acid is converted by LOX enzymes into leukotrienes, which act as pro-inflammatory mediators and are commonly released from myeloid cells. LOX enzymes are widely distributed in both animals and plants. Drugs such as zileuton and meclofenamate, which inhibit LOX enzymes, are frequently employed in the treatment of inflammatory conditions. Similarly,

numerous plants and plant-derived products have demonstrated effectiveness in inhibiting LOX enzymes.

5. Cyclooxygenase Enzymes

Cyclooxygenase enzymes (COX) are responsible for the synthesis of eicosanoids, including prostacyclins, thromboxane, and prostaglandins, via the cyclooxygenase pathway. Two distinct types of cyclooxygenase enzymes, namely COX-1 and COX-2, have been identified. Among them, only COX-2 plays a significant role in pain transmission. Prostaglandins, derived from arachidonic acid and catalyzed by these enzymes, are pivotal in pain perception. Inhibiting cyclooxygenase enzymes offers relief from pain.

COX-1 enzymes are crucial for gastrointestinal tract protection and are widely distributed in platelets, kidneys, and the stomach. They are often referred to as constitutive enzymes. On the other hand, COX-2 enzymes are primarily responsible for synthesizing prostaglandins that induce inflammation and pain. Since COX-2 enzymes are expressed in response to pain, they are termed inducible enzymes. These enzymes are predominantly found in leukocytes and macrophages. Blocking COX-2 enzymes provides pain relief. Specific COX-2 blockers include Meloxicam and Celecoxib, while non-specific COX enzyme blockers include naproxen, diclofenac, and aspirin. Inhibition of COX enzymes leads to a decrease in prostaglandin production, subsequently alleviating pain, inflammatory conditions, and fever. However, it is important to note that many non-steroidal anti-inflammatory drugs (NSAIDs) can cause serious adverse effects such as gastrointestinal bleeding and stomach ulceration.

RESPONSE AND PERCEPTION OF PAIN

Measuring pain in young individuals presents challenges distinct from those encountered with the elderly population. Additionally, females tend to experience higher levels of pain compared to males. Furthermore, pain perception appears to be influenced by cultural factors, with some attributing pain to psychological origins while others view it as a natural occurrence. Certain individuals exhibit heightened sensitivity to pain, leading them to pay greater attention to it and consequently perceive it more intensely. Moreover, there exists an intricate relationship between fatigue, anxiety, and pain, as heightened levels of fatigue and anxiety contribute to an increased perception of pain.

METHODS FOR SELF-REPORTING PAIN ASSESSMENT

In clinical practice, one of the most commonly employed methods for evaluating pain severity is the numerical rating scale (NRS), ranging typically from 0 to 10 points. This method is favored for its simplicity, ease of administration, and relative sensitivity to changes in pain perception following treatment. However, a key limitation of the NRS is its inability to provide pain measurements on a proportional scale. Consequently, if a patient's pain level decreases from 8 to 4 after treatment, it cannot be accurately inferred that the pain has reduced by 50%. While this discrepancy may pose statistical challenges, from a clinical standpoint, any substantial reduction in pain intensity is desirable, irrespective of the precise percentage decrease.

Another widely used pain assessment tool is the verbal rating scale (VRS), wherein patients select a word that best describes their pain intensity (e.g., painless, mild, moderate, severe). Although numerical values are often assigned to each descriptor, VRS are essentially

categorical rather than ordinal or interval scales, unless specific numeric weights for the descriptors have been empirically determined and validated.

Visual Analog Scales (VAS) are frequently employed for pain assessment, wherein patients are presented with a predetermined line anchored with descriptors at each end (e.g., "no pain" and "worst pain imaginable"). Patients then mark their pain intensity along the line, and the distance to the marked point is measured. VAS offers excellent statistical properties, including interval level scaling. However, they can be time-consuming to manage and interpret, and some individuals may struggle to grasp the concept. Both electronic and mechanical versions of VAS are available, which can enhance ease of use and reduce assessment errors.

VARIOUS ADMINISTRATION ROUTES FOR PAIN MANAGEMENT

There exists a range of drug delivery routes and diverse drug formulations (see Table 1). Typically, pain-relieving medications are administered parenterally, in contrast to local administration, which requires the drug to first enter the hypothetical central compartment before reaching the action compartment. Parenteral administration offers significant potential for inducing notable pharmacokinetic alterations in the drug molecule, influenced by its chemical and physical properties. Chemical analgesics are often implicated in numerous drug-target interactions within pain-modulating tissues.

Table 1.

Different drug formulation for the management of pain.

Systemic Administration	Dosage Form	Example	Dose
Oral	Tablets	Paracetamol	0.5 –1 gram every 4–6 hours
	Effervescent tablets	Diclofenac sodium	75–150mg daily in 2–3 divided doses
	Mixture	Ibuprofen	300–400mg 3–4 times a day
	Drops	Aspirin	325–1000mg every 4–6 hours
	Syrup		
Transmucosal	Lozenges	Fentanyl	Initially 100mcg repeated if necessary after 15–30min
Transdermal	Spray	Fentanyl	
	Patches		
	Iontophoresis		
Rectal	Suppository	Paracetamol	60–125mg every 4–6 hours as necessary

Systemic Administration	Dosage Form	Example	Dose
Intravenous	Infusion (continuos/intermittent)	Paracetamol	10mgkg every 4–6 hours, max 30mg/kg
	PCA		
	Bolus injection	Ketorolac	

Oral Solid Analgesics

Oral solid analgesics, typically presented in tablet or capsule form, offer ease of ingestion for patients. Taking tablets while in an upright position and with ample water helps prevent them from becoming lodged in the esophagus. Conversely, lying horizontally may lead to tablet retention in the esophagus, irrespective of the tablet's size and shape. These tablets generally provide analgesic relief within 0.5 to 1 hour following decomposition and absorption, with some exceptions [101].

Liquid Analgesic

Formulations Individuals experiencing reduced saliva production or difficulty swallowing solid foods may exhibit decreased compliance with tablet-based therapies. This challenge is particularly prevalent among older adults and children. Liquid formulations of analgesics, including elixirs, suspensions, and syrups, offer a solution to the swallowing difficulties commonly encountered with tablet regimens. Additionally, chewable tablets or chewing gum aid in drug administration by releasing the medication into saliva prior to entering the esophageal cavity.

Parenteral Administration

Postoperative pain management often relies on the intramuscular (i.m.) administration of opioids such as pethidine and morphine for enhanced analgesia. However, i.m. injections may cause significant discomfort due to the injection itself and irregular tissue penetration from the site of deposition in the muscle compartment to the central area. Research indicates that a higher percentage of patients experience poor analgesia with i.m. injection compared to techniques such as epidural analgesia and patient-controlled analgesia .

Subcutaneous (s.c.) administration can be highly effective for managing specific clinical situations associated with pain, especially in chronic end-stage pain. Pain relief is typically immediate upon subcutaneous drug administration. Nonetheless, s.c. injections may induce mild pain, and their effects may persist for an extended period.

For severe postoperative pain, intravenous (I.V.) administration is often considered the optimal route. Following surgery, permanent venous access is typically established as the patient transitions to the recovery area. Continuous I.V. infusion ensures sustained pain control by maintaining the steady-state concentration of the chosen drug above the minimum effective analgesic blood levels. Parenterally administered nonsteroidal anti-inflammatory drugs (NSAIDs), such as diclofenac sodium, ketorolac, and paracetamol, are favored for their opioid-sparing effect. However, adverse effects associated with oral administration of NSAIDs are not eliminated with parenteral administration. In conscious and swallowing patients, there appears to be no significant advantage of one route over the other .

Non-invasive techniques that bypass the oral cavity, thereby avoiding liver metabolism (first-pass metabolism), are beneficial, particularly for patients who are non-compliant with oral therapy. This approach is also advantageous for low molecular weight lipid-soluble drugs, as the dermis layer offers resistance to the permeation mechanism. Consequently, opioids with high potencies, such as buprenorphine and fentanyl, are often formulated in transdermal patch form for chronic pain management .

Oral transmucosal fentanyl citrate (OTFC) comprises a sugar-filled pill that rapidly releases the drug, allowing for rapid absorption by the oral mucosa. Although OTFC and injectable fentanyl share similar terminal half-lives, OTFC provides a quicker onset of analgesic effect. Consequently, OTFC is predominantly used for chronic pain management and is often preferred over orally administered morphine [107].

ANTI-NOCICEPTIVE MEDICATIONS AND THEIR SIDE EFFECTS

In contemporary medicine, a variety of pain-relieving medications are utilized, sourced from animals, plants, and synthetics. Commonly employed pain-relieving drugs include benzodiazepines, steroids, morphine (opioids), and nonsteroidal anti-inflammatory drugs (NSAIDs), yet their usage is limited by various adverse effects. Among these, NSAIDs are extensively utilized, encompassing drugs like indomethacin, diclofenac, ibuprofen, naproxen, aspirin, and celecoxib. Despite their significant pain-alleviating properties, NSAIDs are associated with adverse effects. For instance, aspirin may induce stomach ulcers, naproxen can lead to tissue swelling and itching, while piroxicam and ibuprofen may cause gastrointestinal disturbances such as diarrhea. Aspirin and indomethacin are linked to tinnitus (ringing in the ears).

Opioids, renowned for their potent analgesic effects, are classified into three subtypes: natural opioids (e.g., morphine and codeine), semi-synthetic opioids (e.g., nalbuphine and oxymorphone), and synthetic opioids (e.g., meperidine and methadone). However, opioids are also associated with numerous adverse effects including constipation, urinary difficulties, sexual dysfunction, and the risk of addiction, abuse, and tolerance with long-term use. Steroids are frequently prescribed for inflammatory conditions such as gout and rheumatoid arthritis .

Steroids are categorized into three subclasses: short-acting steroids (e.g., hydrocortisone and cortisone), intermediate-acting steroids (e.g., prednisolone and prednisone), and long-acting steroids (e.g., betamethasone and dexamethasone). Steroids can induce adverse effects such as glaucoma, insomnia, hypertension, and osteoporosis. Abrupt discontinuation of steroids may lead to withdrawal symptoms such as diarrhea, fainting, and hypoglycemia.

Benzodiazepines are commonly prescribed for anxiety and panic disorders, yet they also have adverse effects including sleep disturbances, depression, and irritability. In addition to these mild effects, benzodiazepines are associated with more serious adverse outcomes such as sexual dysfunction, dependence, and tolerance.

CONCLUSION

Comprehensive comprehension of pain-inducing mechanisms is imperative for the development of effective interventions. Despite significant progress, the molecular intricacies underlying pain pathophysiology remain incompletely elucidated. Pain perception manifests across various levels of the peripheral nerves, spinal cord, and brain, presenting a complex phenomenon. While advancements have been notable, significant gaps persist in our

understanding of pain and its pathophysiology. Therefore, research endeavors focusing on pain, its origins, and therapeutic modalities are both timely and invaluable. It is essential to delve into pain perception, informational processing, and coping mechanisms to pave the way for innovative treatments. Additionally, interdisciplinary investigations are warranted to scrutinize treatment paradigms comprehensively, given that pain manifestation involves intricate interplays of physical, psychological, and socioeconomic factors. Each discipline should remain abreast of emerging developments to navigate the multifaceted landscape of pain.

References:

1. Loeser JD; Treede R-D The Kyoto protocol of IASP Basic Pain Terminology. *Pain*, 2008, 137(3), 473–477. [10.1016/j.pain.2008.04.025] [PubMed] [CrossRef] [Google Scholar]
2. Ferrándiz ML; Nacher-Juan J; Alcaraz MJ Nrf2 as a therapeutic target for rheumatic diseases. *Biochem. Pharmacol*, 2018, 152, 338–346. [10.1016/j.bcp.2018.04.010] [PubMed] [CrossRef] [Google Scholar]
3. Baradaran A; Madihi Y; Merrikhi A; Rafieian-Kopaei M; Nasri H Serum lipoprotein (a) in diabetic patients with various renal function not yet on dialysis.*Pak. J. Med. Sci*, 2013, 29, 354–357. [10.12669/pjms.291(Suppl).3533] [CrossRef] [Google Scholar]
4. Rafieian-Kopaei M; Ghobadi S; Nasri H The Protective Effect of Garlic Extract on Diabetic Nephropathy. *Majallah-i Danishkadah-i Pizishki-i Isfahan*, 2013, •••, 31. [Google Scholar]
5. Khan H Clinical updates on substance-P antagonist in pain management. *Biol. Med. (Aligarh)*, 2014, 6, 4–5. [10.4172/0974-8369.1000e113] [CrossRef] [Google Scholar]
6. McHugh JM; McHugh WB Pain: neuroanatomy, chemical mediators, and clinical implications. *AACN Clin. Issues*, 2000, 11(2), 168–178. [10.1097/00044067-200005000-00003] [PubMed] [CrossRef] [Google Scholar]
7. Nasri H; Rafieian-Kopaei M Protective effects of herbal antioxidants on diabetic kidney disease. *J. Res. Med. Sci*, 2014, 19(1), 82–83. [PMC free article] [PubMed] [Google Scholar]
8. Behradmanesh S; Horestani MK; Baradaran A; Nasri H Association of serum uric acid with proteinuria in type 2 diabetic patients *Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences*, 2013. [PMC free article] [PubMed] [Google Scholar]
9. Lourdudoss C; Di Giuseppe D; Wolk A; Westerlind H; Klareskog L; Alfredsson L; van Vollenhoven RF; Lampa J Dietary Intake of Polyunsaturated Fatty Acids and Pain in spite of Inflammatory Control among Methotrexate Treated Early Rheumatoid Arthritis Patients. *Arthritis Care Res*, 2017. [PMC free article] [PubMed] [Google Scholar]
10. Khan H; Pervaiz A; Intagliata S; Das N; Nagulapalli Venkata KC; Atanasov AG; Najda A; Nabavi SM; Wang D; Pittalà V; Bishayee A The analgesic potential of glycosides derived from medicinal plants. *Daru*, 2020, 28(1), 387–401. [10.1007/s40199-019-00319-7] [PMC free article] [PubMed] [CrossRef] [Google Scholar]
11. Khan H; Saeed M; Gilani A-U-H; Khan MA; Dar A; Khan I The antinociceptive activity of Polygonatum verticillatum rhizomes in pain models.*J. Ethnopharmacol*, 2010, 127(2), 521–527.[10.1016/j.jep.2009.10.003] [PubMed] [CrossRef] [Google Scholar]
12. Khan MA; Khan H; Khan S; Mahmood T; Khan PM; Jabar A Anti-inflammatory, analgesic and antipyretic activities of Physalis minima Linn.*J. Enzyme Inhib. Med. Chem*, 2009, 24(3), 632–637. [10.1080/14756360802321120] [PubMed] [CrossRef] [Google Scholar]

13. Hellerbach J; Schnider O; Besendorf H Synthetic Analgesics: Morphinans: Benzomorphans; *Elsevier*, 2014. [Google Scholar]
14. Crook J; Rideout E; Browne G The prevalence of pain complaints in a general population. *Pain*, 1984, 18(3), 299–314. [10.1016/0304-3959(84)90824-8] [PubMed] [CrossRef] [Google Scholar]
15. Kendig H *Health status of older people project: preliminary findings from a survey of the health and lifestyles of older Australians*; Victorian Health Promotion Foundation, 1996. [Google Scholar]
16. Barberger-Gateau P; Chaslerie A; Dartigues JF; Commenges D; Gagnon M; Salamon R Health measures correlates in French elderly community population: the PAQUID study. *J. Gerontol*, 1992, 47(2), S88–S95. [10.1093/geronj/47.2.S88] [PubMed] [CrossRef] [Google Scholar]
17. Harkins SW Geriatric pain. Pain perceptions in the old. *Clin. Geriatr. Med*, 1996, 12(3), 435–459. [10.1016/S0749-0690(18)30210-6] [PubMed] [CrossRef] [Google Scholar]
18. Von Korff M; Dworkin SF; Le Resche L Graded chronic pain status: an epidemiologic evaluation. *Pain*, 1990, 40(3), 279–291. [10.1016/0304-3959(90)91125-3] [PubMed] [CrossRef] [Google Scholar]
19. Grimby C; Fastbom J; Forsell Y; Thorslund M; Claesson CB; Winblad B Musculoskeletal pain and analgesic therapy in a very old population. *Arch. Gerontol. Geriatr*, 1999, 29(1), 29–43. [10.1016/S0167-4943(99)00021-7] [PubMed] [CrossRef] [Google Scholar]
20. Helme RD; Gibson SJ *Pain in older people Epidemiology of pain*, 1999, 103–112. [Google Scholar]
21. Andersson HI; Ejlertsson G; Leden I; Rosenberg C Chronic pain in a geographically defined general population: studies of differences in age, gender, social class, and pain localization. *Clin. J. Pain*, 1993, 9(3), 174–182. [10.1097/00002508-199309000-00004] [PubMed] [CrossRef] [Google Scholar]
22. Leveille SG; Guralnik JM; Ferrucci L; Hirsch R; Simon-sick E; Hochberg MC Foot pain and disability in older women. *Am. J. Epidemiol*, 1998, 148(7), 657–665. [10.1093/aje/148.7.657] [PubMed] [CrossRef] [Google Scholar]
23. Mobily PR; Herr KA; Clark MK; Wallace RB An epidemiologic analysis of pain in the elderly: The Iowa 65+ Rural Health Study. *J. Aging Health*, 1994, 6, 139–154. [10.1177/089826439400600201] [CrossRef] [Google Scholar]
24. Cook NR; Evans DA; Funkenstein HH; Scherr PA; Ostfeld AM; Taylor JO; Hennekens CH Correlates of headache in a population-based cohort of elderly.*Arch. Neurol*, 1989, 46(12), 1338–1344. [10.1001/archneur.1989.00520480082024] [PubMed] [CrossRef] [Google Scholar]
25. D'Alessandro R; Benassi G; Lenzi PL; Gamberini G; Sacquegna T; De Carolis P; Lugaresi E Epidemiology of headache in the Republic of San Marino. *J. Neurol. Neurosurg. Psychiatry*, 1988, 51(1), 21–27. [10.1136/jnnp.51.1.21] [PMC free article] [PubMed] [CrossRef] [Google Scholar]
26. Kay L; Jørgensen T; Schultz-Larsen K Abdominal pain in a 70-year-old Danish population. An epidemiological study of the prevalence and importance of abdominal pain. *J. Clin. Epidemiol*, 1992, 45(12), 1377–1382. [10.1016/0895-4356(92)90199-W] [PubMed] [CrossRef] [Google Scholar]
27. Sternbach RA Survey of pain in the United States: the Nuprin pain report. *Clin. J. Pain*, 1986, 2, 49–53. [10.1097/00002508-198602010-00008] [CrossRef] [Google Scholar]

28. Magni G; Rossi MR; Rigatti-Luchini S; Merskey H Chronic abdominal pain and depression. Epidemiologic findings in the United States. Hispanic Health and Nutrition Examination Survey. *Pain*, 1992, 49(1), 77–85. [10.1016/0304-3959(92)90191-D] [PubMed] [CrossRef] [Google Scholar]
29. Stoller EP; Forster LE; Portugal S Self-care responses to symptoms by older people. A health diary study of illness behavior. *Med. Care*, 1993, 31(1), 24–42. [10.1097/00005650-199301000-00002] [PubMed] [CrossRef] [Google Scholar]
30. Tibblin G; Bengtsson C; Furunes B; Lapidus L Symptoms by age and sex. The population studies of men and women in Gothenburg, Sweden. *Scand. J. Prim. Health Care*, 1990, 8(1), 9–17. [10.3109/02813439008994923] [PubMed] [CrossRef] [Google Scholar]
31. Abduvaliyevna, O. D. (2024). LATIN'S ROLE AND FUTURE PROSPECTS IN MEDICAL TERMINOLOGY. *American Journal Of Social Sciences And Humanity Research*, *4*(01), 137-149. [PubMed] [CrossRef] [Google Scholar]
32. Олимбоева, Д. А., &Мухамедова, М. С. (2024). ОСОБЕННОСТИ ЛАТИНСКОГО ЯЗЫКА. *SAMARALI TA'LIM VA BARQAROR INNOVATSIYALAR JURNALI*, *2*(2), 56-60. [PubMed] [CrossRef] [Google Scholar]